Juliet obtained her first degree in Natural Sciences (Biochemistry) from the University of Cambridge and a PhD in Developmental Biology from University College London. After her academic studies she then worked for Curis in Cambridge, MA on Hedgehog pathway inhibitors. Following her time at Curis, Juliet moved to Millennium Pharmaceuticals, working on a variety of kinase inhibitors, before moving to Novartis to once more work on developmental pathway inhibitors. Juliet has subsequently worked as Department Head of Pharmacology at Cancer Research Technology, UK and at Sanofi, Cambridge, MA in both cases overseeing the pharmacology of a wide range of projects and in addition building and reorganizing groups. She current heads the Oncology In vivo Pharmacology group at Novartis Institute for Biomedical Research, Cambridge MA.